- Home
- FHN vs ROIV Comparison
FHN vs ROIV Comparison
Compare FHN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FHN | ROIV |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FHN | ROIV |
|---|---|---|
| Price | $23.90 | $22.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $24.40 | $24.31 |
| AVG Volume (30 Days) | 5.6M | ★ 7.4M |
| Earning Date | 01-15-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 20.88 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $3,184,000,000.00 | $20,329,000.00 |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $2.54 | $376.94 |
| P/E Ratio | $14.30 | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $15.19 | $8.73 |
| 52 Week High | $24.11 | $23.23 |
Technical Indicators
Market Signals| Indicator | FHN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 68.53 | 71.54 |
| Support Level | $23.54 | $20.14 |
| Resistance Level | $24.10 | $21.48 |
| Average True Range (ATR) | 0.45 | 0.79 |
| MACD | 0.11 | 0.14 |
| Stochastic Oscillator | 88.89 | 85.33 |
Price Performance
Historical ComparisonAbout FHN First Horizon Corporation
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The company's reportable segments are: Commercial, Consumer & Wealth, Wholesale, and Corporate. The majority of its revenue is generated from Commercial, Consumer & Wealth. The Commercial, Consumer & Wealth segment offers financial products and services, including traditional lending and deposit taking, to commercial and consumer clients in the southern USA and other selected markets.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.